Immune drug discovery from venoms
This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cel...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Jimenez, Rocio [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study - Pedersen, Sidsel Arnspang ELSEVIER, 2018, an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:141 ; year:2018 ; pages:18-24 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.toxicon.2017.11.006 |
|---|
| Katalog-ID: |
ELV041509404 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV041509404 | ||
| 003 | DE-627 | ||
| 005 | 20230625234836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.toxicon.2017.11.006 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000081A.pica |
| 035 | |a (DE-627)ELV041509404 | ||
| 035 | |a (ELSEVIER)S0041-0101(17)30352-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |a 610 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.93 |2 bkl | ||
| 100 | 1 | |a Jimenez, Rocio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune drug discovery from venoms |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. | ||
| 520 | |a This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. | ||
| 650 | 7 | |a Toxin |2 Elsevier | |
| 650 | 7 | |a Venom |2 Elsevier | |
| 650 | 7 | |a Therapeutic |2 Elsevier | |
| 650 | 7 | |a Immune modulation |2 Elsevier | |
| 650 | 7 | |a Immune system |2 Elsevier | |
| 700 | 1 | |a Ikonomopoulou, Maria P. |4 oth | |
| 700 | 1 | |a Lopez, J. Alejandro |4 oth | |
| 700 | 1 | |a Miles, John J. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Pedersen, Sidsel Arnspang ELSEVIER |t Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study |d 2018 |d an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology |g Amsterdam [u.a.] |w (DE-627)ELV001406604 |
| 773 | 1 | 8 | |g volume:141 |g year:2018 |g pages:18-24 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.toxicon.2017.11.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.93 |j Dermatologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 141 |j 2018 |h 18-24 |g 7 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
r j rj |
|---|---|
| matchkey_str |
jimenezrocioikonomopouloumariaplopezjale:2018----:muergicvrf |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
44.93 |
| publishDate |
2018 |
| allfields |
10.1016/j.toxicon.2017.11.006 doi GBV00000000000081A.pica (DE-627)ELV041509404 (ELSEVIER)S0041-0101(17)30352-5 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl Jimenez, Rocio verfasserin aut Immune drug discovery from venoms 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Elsevier Ikonomopoulou, Maria P. oth Lopez, J. Alejandro oth Miles, John J. oth Enthalten in Elsevier Science Pedersen, Sidsel Arnspang ELSEVIER Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study 2018 an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology Amsterdam [u.a.] (DE-627)ELV001406604 volume:141 year:2018 pages:18-24 extent:7 https://doi.org/10.1016/j.toxicon.2017.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.93 Dermatologie VZ AR 141 2018 18-24 7 045F 570 |
| spelling |
10.1016/j.toxicon.2017.11.006 doi GBV00000000000081A.pica (DE-627)ELV041509404 (ELSEVIER)S0041-0101(17)30352-5 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl Jimenez, Rocio verfasserin aut Immune drug discovery from venoms 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Elsevier Ikonomopoulou, Maria P. oth Lopez, J. Alejandro oth Miles, John J. oth Enthalten in Elsevier Science Pedersen, Sidsel Arnspang ELSEVIER Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study 2018 an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology Amsterdam [u.a.] (DE-627)ELV001406604 volume:141 year:2018 pages:18-24 extent:7 https://doi.org/10.1016/j.toxicon.2017.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.93 Dermatologie VZ AR 141 2018 18-24 7 045F 570 |
| allfields_unstemmed |
10.1016/j.toxicon.2017.11.006 doi GBV00000000000081A.pica (DE-627)ELV041509404 (ELSEVIER)S0041-0101(17)30352-5 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl Jimenez, Rocio verfasserin aut Immune drug discovery from venoms 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Elsevier Ikonomopoulou, Maria P. oth Lopez, J. Alejandro oth Miles, John J. oth Enthalten in Elsevier Science Pedersen, Sidsel Arnspang ELSEVIER Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study 2018 an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology Amsterdam [u.a.] (DE-627)ELV001406604 volume:141 year:2018 pages:18-24 extent:7 https://doi.org/10.1016/j.toxicon.2017.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.93 Dermatologie VZ AR 141 2018 18-24 7 045F 570 |
| allfieldsGer |
10.1016/j.toxicon.2017.11.006 doi GBV00000000000081A.pica (DE-627)ELV041509404 (ELSEVIER)S0041-0101(17)30352-5 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl Jimenez, Rocio verfasserin aut Immune drug discovery from venoms 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Elsevier Ikonomopoulou, Maria P. oth Lopez, J. Alejandro oth Miles, John J. oth Enthalten in Elsevier Science Pedersen, Sidsel Arnspang ELSEVIER Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study 2018 an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology Amsterdam [u.a.] (DE-627)ELV001406604 volume:141 year:2018 pages:18-24 extent:7 https://doi.org/10.1016/j.toxicon.2017.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.93 Dermatologie VZ AR 141 2018 18-24 7 045F 570 |
| allfieldsSound |
10.1016/j.toxicon.2017.11.006 doi GBV00000000000081A.pica (DE-627)ELV041509404 (ELSEVIER)S0041-0101(17)30352-5 DE-627 ger DE-627 rakwb eng 570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl Jimenez, Rocio verfasserin aut Immune drug discovery from venoms 2018transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Elsevier Ikonomopoulou, Maria P. oth Lopez, J. Alejandro oth Miles, John J. oth Enthalten in Elsevier Science Pedersen, Sidsel Arnspang ELSEVIER Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study 2018 an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology Amsterdam [u.a.] (DE-627)ELV001406604 volume:141 year:2018 pages:18-24 extent:7 https://doi.org/10.1016/j.toxicon.2017.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.93 Dermatologie VZ AR 141 2018 18-24 7 045F 570 |
| language |
English |
| source |
Enthalten in Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study Amsterdam [u.a.] volume:141 year:2018 pages:18-24 extent:7 |
| sourceStr |
Enthalten in Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study Amsterdam [u.a.] volume:141 year:2018 pages:18-24 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Dermatologie |
| institution |
findex.gbv.de |
| topic_facet |
Toxin Venom Therapeutic Immune modulation Immune system |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study |
| authorswithroles_txt_mv |
Jimenez, Rocio @@aut@@ Ikonomopoulou, Maria P. @@oth@@ Lopez, J. Alejandro @@oth@@ Miles, John J. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV001406604 |
| dewey-sort |
3570 |
| id |
ELV041509404 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041509404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625234836.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.toxicon.2017.11.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000081A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041509404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0041-0101(17)30352-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.93</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jimenez, Rocio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune drug discovery from venoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Venom</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune modulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune system</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ikonomopoulou, Maria P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopez, J. Alejandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miles, John J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Pedersen, Sidsel Arnspang ELSEVIER</subfield><subfield code="t">Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study</subfield><subfield code="d">2018</subfield><subfield code="d">an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV001406604</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:141</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:18-24</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.toxicon.2017.11.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.93</subfield><subfield code="j">Dermatologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">141</subfield><subfield code="j">2018</subfield><subfield code="h">18-24</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Jimenez, Rocio |
| spellingShingle |
Jimenez, Rocio ddc 570 ddc 610 bkl 44.93 Elsevier Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Immune drug discovery from venoms |
| authorStr |
Jimenez, Rocio |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV001406604 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl Immune drug discovery from venoms Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system Elsevier |
| topic |
ddc 570 ddc 610 bkl 44.93 Elsevier Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system |
| topic_unstemmed |
ddc 570 ddc 610 bkl 44.93 Elsevier Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system |
| topic_browse |
ddc 570 ddc 610 bkl 44.93 Elsevier Toxin Elsevier Venom Elsevier Therapeutic Elsevier Immune modulation Elsevier Immune system |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m p i mp mpi j a l ja jal j j m jj jjm |
| hierarchy_parent_title |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study |
| hierarchy_parent_id |
ELV001406604 |
| dewey-tens |
570 - Life sciences; biology 610 - Medicine & health |
| hierarchy_top_title |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV001406604 |
| title |
Immune drug discovery from venoms |
| ctrlnum |
(DE-627)ELV041509404 (ELSEVIER)S0041-0101(17)30352-5 |
| title_full |
Immune drug discovery from venoms |
| author_sort |
Jimenez, Rocio |
| journal |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study |
| journalStr |
Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
18 |
| author_browse |
Jimenez, Rocio |
| container_volume |
141 |
| physical |
7 |
| class |
570 610 570 DE-600 610 DE-600 610 VZ 44.93 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Jimenez, Rocio |
| doi_str_mv |
10.1016/j.toxicon.2017.11.006 |
| dewey-full |
570 610 |
| title_sort |
immune drug discovery from venoms |
| title_auth |
Immune drug discovery from venoms |
| abstract |
This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. |
| abstractGer |
This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. |
| abstract_unstemmed |
This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Immune drug discovery from venoms |
| url |
https://doi.org/10.1016/j.toxicon.2017.11.006 |
| remote_bool |
true |
| author2 |
Ikonomopoulou, Maria P. Lopez, J. Alejandro Miles, John J. |
| author2Str |
Ikonomopoulou, Maria P. Lopez, J. Alejandro Miles, John J. |
| ppnlink |
ELV001406604 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.toxicon.2017.11.006 |
| up_date |
2024-07-06T20:19:15.664Z |
| _version_ |
1803862310298583040 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041509404</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625234836.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.toxicon.2017.11.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000081A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041509404</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0041-0101(17)30352-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.93</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Jimenez, Rocio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immune drug discovery from venoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review catalogues recent advances in knowledge on venoms as standalone therapeutic agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects the immune system. We discuss venoms and venom-derived compounds that affect total immune cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune response during infectious disease and cancer and down-regulating the immune response during autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, combining recent advances in venomics with progress in low cost, high-throughput screening platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming years.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Toxin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Venom</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune modulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune system</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ikonomopoulou, Maria P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopez, J. Alejandro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miles, John J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Pedersen, Sidsel Arnspang ELSEVIER</subfield><subfield code="t">Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study</subfield><subfield code="d">2018</subfield><subfield code="d">an interdisciplinary journal on the toxins derived from animals, plants and microorganisms : official journal of The International Society on Toxinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV001406604</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:141</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:18-24</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.toxicon.2017.11.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.93</subfield><subfield code="j">Dermatologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">141</subfield><subfield code="j">2018</subfield><subfield code="h">18-24</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.400667 |